Biopure Announces First Quarter 2003 Conference Call and Webcast.Business Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2003 Biopure Corporation (Nasdaq:BPUR BPUR Biopure Corporation (stock symbol) ) will announce its financial results for the first fiscal quarter ended January 31, 2003, on Thursday, February 20, 2003, after the market closes. Following the announcement, Biopure President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Thomas A. Moore will host a conference call at 4:30 p.m. Eastern Standard Time (EST EST electroshock therapy. EST abbr. electroshock therapy ) to review these results and the company's activities. The dial-in numbers are 1-800-387-5428 (US/Canada) and 1-706-634-1328 (International). A live audio webcast of the conference call will be available from the investor section of Biopure's web site at www.biopure.com and will be archived for 30 days. The webcast can also be heard by individual investors at www.companyboardroom.com and by institutional investors who subscribe to StreetEvents at www.streetevents.com. An audio replay of the conference call will be available from approximately 7:30 p.m. EST, February 20, 2003, until midnight February 28, 2003. To access the replay, dial 1-800-642-1687 (US/Canada) or 1-706-645-9291 (International/Local) and reference conference ID number 8137481. Biopure Corporation Biopure Corporation, headquartered in Cambridge, Mass., is a leading developer, manufacturer and marketer of oxygen therapeutics, a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) (hemoglobin glutamer - 250 (bovine)) is commercially available in South Africa for the treatment of adult surgical patients who are acutely anemic and for the purpose of eliminating, delaying or reducing the need for allogenic allogenic /al·lo·gen·ic/ (-jen´ik) allogeneic. allogenic, adj from individuals of the same species. Tissue transplanted from one person to another is said to be allogenic. red blood cell red blood cell: see blood. transfusion in these patients. Biopure's application to market Hemopure in the United States for a similar indication in elective orthopedic surgical patients is currently being reviewed by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ), and the company plans to file additional applications in Europe and other markets. Hemopure is in earlier stages of clinical development for use in cancer and in preclinical development for trauma and ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic events such as heart attack and stroke. Biopure's veterinary product Oxyglobin(R) (hemoglobin glutamer - 200 (bovine)), the only oxygen therapeutic approved by the FDA and the European Commission, is indicated for the treatment of anemia in dogs. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion